BioPharma Resources

NDA 021925 · Takeda Pharms USA

Duetact

Glimepiride, Pioglitazone Hydrochloride · Oral · Sulfonylurea

Last checked: Nov 19, 2026Latest source record: Dec 21, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Jul 28, 2006

Approved uses

2

Original approval plus efficacy supplements

Registered trials

252

102 Phase 3, 1 recruiting

FAERS reports

93

48 serious, 8 with death reported

AI brief across all sources

Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CONGESTIVE HEART FAILURE Thiazolidinediones, including pioglitazone, which is a component of pioglitazone and glimepiride tablets, cause or exacerbate congestive heart failure in some patients [see Warnings and Precautions (5.1) ] . After initiation of pioglitazone and glimepiride tablets and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If heart failure develops, it should be managed according to current standards of care and discontinuation or dose reduction of pioglitazone and glimepiride tablets must be considered [see Warnings and Precautions (5.1) ] . Pioglitazone and glimepiride tablets are not recommended in patients with symptomatic heart failure [see Warnings and Precautions (5.1) ] . Initiation of pioglitazone and glimepiride tablets in patients with established...

What it is approved for

From the label in effect Dec 12, 2025.

Pioglitazone and glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and sulfonylurea or who have inadequate glycemic control on a thiazolidinedione alone or a sulfonylurea alone [see Clinical Studies (14) ] . Pioglitazone and glimepiride tablets are a thiazolidinedione and a sulfonylurea combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both pioglitazone and glimepiride is appropriate. ( 1 ) Important Limitations of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis. ( 1 ) Important Limitations of Use Pioglitazone exerts its antihyperglycemic effect only in the presence of endogenous insulin. Pioglitazone and glimepiride tablets should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. Use caution in patients with liver disease [see Warnings and Precautions (5.5) ].

Mechanism: Pioglitazone and glimepiride tablets combine 2 antihyperglycemic agents with different mechanisms of action to improve glycemic control in patients with type 2 diabetes: pioglitazone, a member of the thiazolidinedione class, and glimepiride, a member of the sulfonylurea class. Thiazolidinediones are insulin-sensitizing agents that act primarily by enhancing peripheral glucose utilization, whereas sulfonylureas are insulin secretagogues that act primarily by stimulating release of insulin from functioning pancreatic beta cells. Pioglitazone Pioglitazone is a thiazolidinedione that depends on...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • DUETACT · GLIMEPIRIDE 4MG; PIOGLITAZONE HYDROCHLORIDE 30MG · TABLET, ORAL · Prescription · TE AB
  • DUETACT · GLIMEPIRIDE 2MG; PIOGLITAZONE HYDROCHLORIDE 30MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Glimepiride" as an intervention, any sponsor and status, largest first.

All 252 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased9
  • bladder cancer8
  • drug ineffective8
  • dyspnoea7
  • nausea7
  • vomiting6
  • depression5
  • dizziness5
  • flushing5
  • malaise5
  • anxiety4
  • asthenia4

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20074
200814
20097
20105
201116
20124
20133
20142
201514
20167
20182
20194
20203
20211
20222
20233
20262

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 468 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.